Previous 10 | Next 10 |
2023-05-04 16:48:10 ET Puma Biotechnology press release ( NASDAQ: PBYI ): Q1 Non-GAAP EPS of $0.09. Revenue of $52.8M (+15.5% Y/Y). For further details see: Puma Biotechnology Non-GAAP EPS of $0.09, revenue of $52.8M
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023. Unless otherwise stated, all comparisons are for the first quarter of 2023 compared to the first quarter of 2022. Product revenue, net consists entirel...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 4, 2023, following the release of its first quarter 2023 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-...
2023-04-03 11:28:47 ET Summary Today, we put a small biotech company called Puma Biotechnology, Inc. in the spotlight. The stock appears cheap on a price to sales basis, but the company had been dogged by a lawsuit and some other issues. Is Puma a buy at just over three bucks ...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer have been published online in JAM...
2023-03-08 12:42:49 ET The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Puma Biotechnology, Inc. 2022 Q4 - Results - Earnings Call Presentation
Puma Biotechnology ( NASDAQ: PBYI ) stock fell ~15% on Friday after the company saw a loss in Q4, despite rise in revenue. Adjusted net loss was -$3M, compared to non-GAAP adjusted net income of $8.4M in Q4 2021. Net loss was -$5.6M, compared to net income of $4.2Min Q4 ...
Gainers: Altamira Therapeutics ( CYTO ) +86% . Bullfrog AI ( BFRG ) +26% . Seer ( SEER ) +25% . Ardelyx ( ARDX ) +23% . Lucy Scientific Discovery ( LSDI ) +16% . Losers: Praxis Precision Medicines ( PRAX ) -55% . Veru (...
Puma Biotechnology, Inc. (PBYI) Q4 2022 Earnings Conference Call March 02, 2023, 04:30 PM ET Company Participants Mariann Ohanesian - Senior Director of IR Alan Auerbach - CEO, President and Chairman Maximo Nougues - CFO Jeff Ludwig - Chief Commercial Officer ...
Puma Biotechnology press release ( NASDAQ: PBYI ): Q4 Non-GAAP EPS of -$0.07. Revenue of $65.7M (+18.6% Y/Y) beats by $8.64M . Sees Q1 2023 net product revenue of $43M to $46M, royalty revenue of $4M to $6M. Sees FY 2023 net product revenue of $205M to $210M, royalty r...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....